Synonym
SNG1153; SNG-1153; SNG 1153
IUPAC/Chemical Name
3,5,7-Trihydroxy-8-(3-methyl-but-2-enyl)-2-(4-trifluoromethyl-phenyl)-chromen-4-one
InChi Key
OXHMDMVBLQNMGP-UHFFFAOYSA-N
InChi Code
InChI=1S/C21H17F3O5/c1-10(2)3-8-13-14(25)9-15(26)16-17(27)18(28)19(29-20(13)16)11-4-6-12(7-5-11)21(22,23)24/h3-7,9,25-26,28H,8H2,1-2H3
SMILES Code
O=C1C(O)=C(C2=CC=C(C(F)(F)F)C=C2)OC3=C1C(O)=CC(O)=C3C/C=C(C)\C
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Biological target:
SNG-1153 is an ER-alpha36 modulator.
In vivo activity:
This study demonstrates that SNG-1153 may be a novel therapeutic agent to treat human lung cancer. SNG-1153 was able to attenuate tumor formation in NOD/SCID (non-obese diabetic/severe combined immunodeficient) mice injected with lung tumorsphere cells. SNG-1153 also induced β-catenin phosphorylation and down-regulated β-catenin.
Reference: Oncotarget. 2016 Jul 19;7(29):45158-45170. https://pubmed.ncbi.nlm.nih.gov/27281614/
Preparing Stock Solutions
The following data is based on the
product
molecular weight
406.36
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
Formulation protocol:
1. Chen M, Turhan AG, Ding H, Lin Q, Meng K, Jiang X. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex. Oncotarget. 2017 Jul 4;8(27):43662-43677. doi: 10.18632/oncotarget.18216. PMID: 28599273; PMCID: PMC5546432.
2. Liu S, Guo Y, Wang J, Zhu H, Han Y, Jin M, Wang J, Zhou C, Ma J, Lin Q, Wang Z, Meng K, Fu X. A novel anticancer agent SNG1153 inhibits growth of lung cancer stem/progenitor cells. Oncotarget. 2016 Jul 19;7(29):45158-45170. doi: 10.18632/oncotarget.9783. PMID: 27281614; PMCID: PMC5216713.
In vivo protocol:
1. Chen M, Turhan AG, Ding H, Lin Q, Meng K, Jiang X. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex. Oncotarget. 2017 Jul 4;8(27):43662-43677. doi: 10.18632/oncotarget.18216. PMID: 28599273; PMCID: PMC5546432.
2. Liu S, Guo Y, Wang J, Zhu H, Han Y, Jin M, Wang J, Zhou C, Ma J, Lin Q, Wang Z, Meng K, Fu X. A novel anticancer agent SNG1153 inhibits growth of lung cancer stem/progenitor cells. Oncotarget. 2016 Jul 19;7(29):45158-45170. doi: 10.18632/oncotarget.9783. PMID: 27281614; PMCID: PMC5216713.
1: Chen M, Turhan AG, Ding H, Lin Q, Meng K, Jiang X. Targeting BCR-ABL+ stem/progenitor cells and BCR-ABL-T315I mutant cells by effective inhibition of the BCR-ABL-Tyr177-GRB2 complex. Oncotarget. 2017 Jul 4;8(27):43662-43677. doi: 10.18632/oncotarget.18216. PubMed PMID: 28599273; PubMed Central PMCID: PMC5546432.
2: Liu S, Guo Y, Wang J, Zhu H, Han Y, Jin M, Wang J, Zhou C, Ma J, Lin Q, Wang Z, Meng K, Fu X. A novel anticancer agent SNG1153 inhibits growth of lung cancer stem/progenitor cells. Oncotarget. 2016 Jul 19;7(29):45158-45170. doi: 10.18632/oncotarget.9783. PubMed PMID: 27281614; PubMed Central PMCID: PMC5216713.
